Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI ( https://c212.net/c/link/?t=0&l=en&o=2949950-1&h=526957075&u=http%3A%2F%2Fwww.pharma.ai%2F&a=Pharma.AI ) platform in this collaboration. It will use its proprietary Pandomics Discovery Platform ( https://c212.net/c/link/?t=0&l=en&o=2949950-1&h=1887706065&u=https%3A%2F%2Fpandomics.com%2Fcovidomics%2F&a=Pandomics+Discovery+Platform ) to identify novel targets for senolytic drugs and Chemistry42 platform ( https://c212.net/c/link/?t=0&l=en&o=2949950-1&h=4114055493&u=https%3A%2F%2Finsilico.com%2Fchemistry42%2F&a=Chemistry42+platform ) for a molecular generation. This collaboration brings together Insilico's state-of-art artificial intelligence (AI) technologies in drug discovery with Taisho's expertise in drug development, aimed to extend the human healthspan. Photo - https://mma.prnewswire.com/media/1312850/Insilico_Taisho.jpg "We're delighted to collaborate with Taisho pharmaceutical, a well-recognized leader in the pharmaceutical industry and healthcare sector. It is believed that aging is a universal phenomenon that we cannot stop. However, emerging scientific evidence has shown that one may be able to reverse some of the age-associated processes. Through this collaboration, we will adopt our AI-powered drug discovery suites together with Taisho's validation platform to explore the new space of anti-aging solutions," said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan, a fully-owned subsidiary of Insilico Medicine Under the terms of the agreement, Insilico Medicine will receive an upfront payment and milestone payments upon achievement of specified goals. Insilico Medicine will be responsible for early research phase target identification and molecular generation and Taisho will work collaboratively with Insilico in validating the results in various in vitro and in vivo assays. Taisho has the exclusive option to acquire Insilico's co-ownership of the successfully developed programs under agreed payment. "It is our great honor to be collaborating with the scientists of Taisho Pharmaceutical, one of the top 100 pharmaceutical companies in the world operating since 1912. The high level of the scientists we are interfacing, and our previous successes in the application of the Pharma.AI platform for discovery of novel targets and molecules in fibrosis, and previous experience in senolytic drug discovery give us confidence that this collaboration will be successful," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. About Taisho Pharmaceutical Co., Ltd. https://www.taisho.co.jp/global/ Media Contact For further information, images or interviews, please contact: ai@insilico.com About Insilico Medicine Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/ SOURCE: Insilico Medicine Hong Kong Limited